Case report: Vedolizumab in Oral Crohn’s disease: the downsides of a gut-specific therapy for a multi-site disease
2024

Vedolizumab in Oral Crohn’s Disease: Limitations of a Gut-Specific Therapy

Sample size: 1 publication Evidence: low

Author Information

Author(s): Harte Molly, Macken John, Zou Lifong, Fortune Farida

Primary Institution: Royal London Hospital, Barts Health NHS Trust

Hypothesis

Can vedolizumab effectively manage oral manifestations of Crohn's disease?

Conclusion

Vedolizumab is effective for intestinal Crohn's disease but does not alleviate oral symptoms due to its gut-specific action.

Supporting Evidence

  • Vedolizumab improved gut symptoms significantly but worsened oral symptoms.
  • The absence of MAdCAM-1 in oral tissues limits vedolizumab's effectiveness for oral Crohn's disease.
  • Multidisciplinary management is crucial for patients with both oral and intestinal manifestations of Crohn's disease.

Takeaway

This study shows that a medicine that works well for the gut might not help with mouth problems in Crohn's disease.

Methodology

Case report of a 28-year-old male patient with oral and intestinal Crohn's disease treated with vedolizumab.

Limitations

The study is based on a single case report, limiting generalizability.

Participant Demographics

28-year-old male patient with Crohn's disease.

Digital Object Identifier (DOI)

10.3389/fmed.2024.1485394

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication